Tibotec begins recruiting for hepatitis C drug trial - London

[Guest guest]

http://www.hayspharma.com/news/news-item/18829467

Tibotec begins recruiting for hepatitis C drug trial

16 Oct 2008

Tibotec has revealed it has commenced patient recruitment for a clinical trial

of a hepatitis C virus (HCV) treatment.

The & company said the phase-three clinical study will evaluate

the efficacy of telaprevir, its investigational protease inhibitor, in patients

who previously had unsuccessful treatment with peginterferon.

Being co-developed by Tibotec and Vertex Pharmaceuticals, telaprevir will be

assessed as part of a combination medicine with peginterferon and ribavarin,

which will be compared to peginterferon and ribavarin alone - the current

standard of care.

Pomerantz, president of Tibotec research and development, indicated that

the firm is excited about the upcoming study.

He commented that the medicine is " potentially the first direct antiviral for

the treatment of HCV, which may provide a new option for patients who have

failed the current standard of care " .